GENMAB AS SP.ADR/1/10DK 1 (GE91) — Cash Flow Reinvestment Rate
GENMAB AS SP.ADR/1/10DK 1 (GE91) has a Cash Flow Reinvestment Rate of 5.54x as of December 2025, reinvesting €1.67 Billion (capex €13.00 Million plus investments €1.66 Billion) from operating cash flow of €301.00 Million. Explore reinvestment intensity of GENMAB AS SP.ADR/1/10DK 1 to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
GENMAB AS SP.ADR/1/10DK 1 Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for GENMAB AS SP.ADR/1/10DK 1 across 5 annual periods. Also explore balance sheet size of GENMAB AS SP.ADR/1/10DK 1 for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
Year-by-year capital reinvestment analysis for GENMAB AS SP.ADR/1/10DK 1. For live market cap and broader valuation context, see GENMAB AS SP.ADR/1/10DK 1 (GE91) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.42x | €1.68 Billion | €1.19 Billion | €55.00 Million | ▲ +274.0% |
| 2024 | 0.38x | €411.16 Million | €1.08 Billion | €42.41 Million | ▲ +118.3% |
| 2023 | 0.17x | €190.34 Million | €1.10 Billion | €55.83 Million | ▼ -75.4% |
| 2022 | 0.71x | €397.39 Million | €563.05 Million | €45.63 Million | ▲ +63.6% |
| 2021 | 0.43x | €146.30 Million | €339.18 Million | €38.36 Million | — |